Filing Flows › Mimedx Group (MDXG) › Guidance & outlook
Mimedx Group (MDXG) guidance and outlook
Mimedx Group (MDXG) lowered its guidance on Oct 28, 2026: Revenue $250M–$260M for FY2026; EBITDA margin 20% for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $250M–$260M | lowered |
| EBITDA margin | FY2026 | 20% | reaffirmed |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Mimedx Group's latest quarter
Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%, net loss $8.7M, operating cash flow $3.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Mimedx Group raise or lower its guidance?
Mimedx Group (MDXG) lowered its guidance on Oct 28, 2026: Revenue $250M–$260M for FY2026; EBITDA margin 20% for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.